Nurix Therapeutics, Inc. (NRIX)

14,13 +0,55 (+4,05%) Börsenschluss: 04:00PM EDT

Nurix Therapeutics, Inc.

1700 Owens Street
Suite 205
San Francisco, CA 94158
United States
415 660 5320
https://www.nurixtx.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 284

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Arthur T. Sands M.D., Ph.D.	CEO, President & Director	986,32k	N/A	1962
Mr. Johannes Van Houte	Chief Financial Officer	681,98k	N/A	1966
Dr. Gwenn M. Hansen Ph.D.	Chief Scientific Officer	702,75k	N/A	1971
Dr. John Kuriyan Ph.D.	Founder & Member of Scientific Advisory Board	N/A	N/A	N/A
Mr. Michael Rapé Ph.D.	Founder & Member of Scientific Advisory Board	N/A	N/A	N/A
Dr. Arthur Weiss M.D., Ph.D.	Founder & Member of Scientific Advisory Board	N/A	N/A	N/A
Rita Kwong	Senior Accounting Manager	N/A	N/A	N/A
Dr. Christine Ring J.D., Ph.D.	Chief Legal Officer, Secretary & Chief Compliance Officer	595,83k	599,89k	1965
Mr. Eric C. Schlezinger J.D.	Chief People Officer	N/A	N/A	1967
Dr. Jason Kantor Ph.D.	Chief Business Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Corporate Governance

Nurix Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 9. Die grundlegenden Scores sind Audit: 8, Vorstand: 5, Shareholderrechte: 8, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.